Love Hemp Ltd. is also an ethical promoter of high-quality CBD products who does not engage in dubious advertising techniques. Their product information and labelling are transparent and all products possess third-party certification. They recently partnered with UFC fighters when they saw how CBD had changed their lives. These may not be the ultimate reference models for a health-conscious market, but they’re certainly an interesting testimonial to listen to, as they’re very conscious of their performance and value the importance of recovery after strenuous mental stress and physical exercise. Love Hemp is responsible for breaking ground and shifting the UK public’s perception of cannabis as a source of vegan goodness for people of all ages and creeds. Visit the Love Hemp collection.
PharmaHemp is another gem of a company to come from tiny, green Slovenia. Their hemp fields are also open air, organic and drop-dead gorgeous. They are based in micro-locations in Eastern Slovenia, the Gorenjska region and Croatia. Areas that traditionally grew cannabis before its prohibition. All these locations continue to grow organically. Founded by Andrej Susnik in 2011, engineer and entrepreneur who has worked in the field of cannabis extraction since 1964, PharmaHemp is a solid European player with the leverage of experience and a great focus on organic production. By using supercritical CO2 extraction, PharmaHemp ensures that all their extracts are full spectrum, i.e. containing not only CBD (cannabidiol), but also other cannabinoids, terpenes, amino acids, essential fatty acids (omega oils), bioflavonoids and many other phytonutrients. Their cutting-edge production facilities are matched with very slick packaging and design.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
The CB1 receptors are mostly present in the brain, but some are located throughout your body. These receptors deal with movement and coordination, emotions, thinking, memories, pain, mood, appetite, and other function. The CB2 receptors are mostly in the immune system. They affect pain and inflammation. CBD works in two ways. It attaches itself to these receptors while stimulating the body to produce more cannabinoids on its own naturally. Amazingly, CBD assists the body in learning to heal itself.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
Although CBD oils aren’t regulated by the FDA, purchasing products stateside from one of the nine states where recreational and medical cannabis use is legal will likely result in a higher-quality product than buying one made with hemp-derived CBD oil imported from abroad, says Martin Lee, director of Project CBD, a nonprofit that promotes medical research into CBD.
×